Ann: Quarterly Activities Report and Cashflow, page-48

The medium term problems of the company are obvious and investors see that an entry lower can be achieved later on. The 87m shares to be issued under a resolution at the AGM and another capital raise coming in have scared buyers and sellers are currently dominating this share

Also the research expenditure would have been expected to be much higher to fast track the tests. As shareholders, we expect that the company would try to get this test to the market asap to generate revenues and potential profits. It's possible that BD1 will consider partnering with another company to do the medical research but that's just all speculation